University of Florida

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Florida sits in the top decile of US sponsors by registered trial count (#29 of 15,742 sponsors by registered trial count).

1,106 total trials 170 currently recruiting 754 completed early-phase tilt top decile by trial count

University of Florida: 1,106 sponsored US clinical trials, 170 recruiting.

University of Florida sponsors 1,106 registered US clinical trials on ClinicalTrials.gov, 170 of them currently recruiting, and 754 completed. 103 of these trials are in Phase 3-4 (later-stage) and 232 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 17 trials.

Top-decile sponsor footprint

University of Florida ranks in the top decile of sponsors by registered trial count (#29 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

754 of 855 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,106 total, page 21 of 23

TERMINATED Phase 2

Study of Temozolomide to Treat Newly Diagnosed Brain Metastases

NCT00717275

COMPLETED NA

Anterior Cruciate Ligament Reconstruction and Plyometric Exercise

NCT01851655

COMPLETED Phase 2

Study of Capecitabine to Treat Recurrent High Grade Gliomas

NCT00717197

COMPLETED

Antimicrobial Susceptibility Patterns of N. Gonorrhea Isolates in an Era of Quinolone Resistance

NCT00692822

COMPLETED NA

Rural Lifestyle Intervention Treatment Effectiveness Trial

NCT00912652

TERMINATED

Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx

NCT00797290

COMPLETED NA

Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm

NCT01111110

TERMINATED

Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility

NCT00692783

COMPLETED NA

Proton Therapy for Low and Intermediate Risk Prostate Cancer

NCT00693238

COMPLETED Phase 1

Neulasta in Type 1 Diabetes

NCT00662519

COMPLETED Phase 2

Adjunctive Neuromuscular Electrical Stimulation for the Rehabilitation of Swallowing

NCT01279824

COMPLETED Phase 4

Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure

NCT00669279

COMPLETED NA

Proton Therapy for Unresectable Cancer (CA) of Pancreas

NCT00685763

COMPLETED

Pharmacokinetics and Pharmacodynamics of Fructose

NCT00661947

COMPLETED NA

Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay

NCT00643578

TERMINATED NA

LXRA Gene Polymorphisms and Response to Fenofibrate

NCT00644592

COMPLETED NA

Do Self-Rated Performance Status Scores Correlate With Health-Care-Provider-Scores?

NCT00735111

COMPLETED NA

Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers

NCT00607347

COMPLETED NA

Vitamin B6 Dependence of One-Carbon Metabolism

NCT00877812

COMPLETED Phase 4

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

NCT01006889

COMPLETED

Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis

NCT00601068

COMPLETED

Induction Related BK Viremia in Renal Transplant Patients

NCT00610961

COMPLETED

Shoulder Rotational Flexibility and Throwing Arm Injuries of Baseball Pitchers

NCT00631826

TERMINATED

Proton Radiation Therapy for Pituitary Adenoma

NCT00798057

TERMINATED Phase 2

Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar

NCT00475332

TERMINATED

Photon/Proton Radiation Therapy for Oropharyngeal Cancers

NCT00797446

COMPLETED Phase 2

Use of Fenofibrate for Primary Biliary Cirrhosis

NCT00575042

COMPLETED Phase 1

Training the Arm and Hand After Stroke Using Auditory Rhythm Cues

NCT00523523

TERMINATED NA

COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI

NCT00523367

COMPLETED

Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy

NCT01238341

COMPLETED NA

The Clinical Utility of Overtube Use at the Time of Endoscopy

NCT00861263

COMPLETED Phase 4

Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

NCT00998335

COMPLETED Phase 1

Mechanisms of Neural Mobilization in the Treatment of Chronic Pain

NCT00929123

COMPLETED Phase 4

Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)

NCT00887510

COMPLETED NA

Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson's Disease

NCT00955032

COMPLETED Phase 1

Treating Intention In Aphasia: Neuroplastic Substrates

NCT00567242

COMPLETED NA

Prevention of Low Back Pain in the Military

NCT00373009

COMPLETED

Restoring Walking in Non-ambulatory Children With Severe Chronic Spinal Cord Injury (SCI) (Kids STEP Study)

NCT00488280

COMPLETED Phase 3

Phase III Trial of Coenzyme Q10 in Mitochondrial Disease

NCT00432744

COMPLETED

Proton Therapy for Chordomas and/or Chondrosarcomas

NCT00797602

COMPLETED NA

Mechanisms and Treatment Response of Aggressive Periodontitis in Children

NCT01330719

COMPLETED

The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Management of Pancreaticobiliary Disorders

NCT00861198

COMPLETED NA

Accuracy of Spybite Forceps When Compared to Conventional Sampling Methods

NCT01227382

COMPLETED NA

Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor

NCT00954421

TERMINATED

Mechanism of Percutaneous Revascularization for Coronary Bifurcation Disease

NCT00429052

COMPLETED Phase 2

Biological Effects of Weight Loss In Older, Obese Women

NCT01032733

COMPLETED

Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity

NCT00375089

COMPLETED

Photon/Proton Radiation Therapy for Cancers of the Nasal Cavity and/or Paranasal Sinuses

NCT00797498

COMPLETED Phase 2

Post Stroke Hand Functions: Bilateral Movements and Electrical Stimulation Treatments

NCT00369668

COMPLETED NA

Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease

NCT00379808

← Previous Page 21 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 123
Phase 2 109
Phase 3 13
Phase 4 90

What is open in the University of Florida pipeline

170 recruiting of 1,106 indexed (15% open); 754 completed (68%).

Phase mix: 103 late (III/IV) vs 232 early (I/II) (early-phase heavy).

Top condition: Coronary Artery Disease (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Florida: open-pipeline peers nationwide

Peers matched on 1,106 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

University of Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of FloridaUniversity of North Carolina, Chapel HillWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthArrowhead Regional Medical CenterAurinia PharmaceuticalsBronx VA Medical CenterCandel Therapeutics
University of Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,106 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this University of Florida page

1,106 registered trials is a research-attention snapshot, not an endorsement of University of Florida or any single study.

  • 170 of University of Florida's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Coronary Artery Disease is the condition University of Florida studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Florida pipeline card: 1,106 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.